
    
The genomic variant c.2T>A p.Met1? rs1170153450 is located in the ASCL1 gene, which encodes the Achaete-scute complex homolog 1 (ASCL1), a transcription factor that plays a crucial role in the determination and differentiation of neuronal precursors in the developing nervous system. ASCL1 is also involved in the regulation of gene expression associated with neurogenesis and has been implicated in the development of certain types of neuroendocrine tumors due to its role in the differentiation of neural and neuroendocrine cells.The c.2T>A variant results in the loss of the canonical start codon (ATG to AAG), which is predicted to lead to a start lost mutation. This type of mutation can have significant effects on the protein since it may prevent the initiation of translation, potentially leading to a complete loss of protein function or the production of a truncated protein with compromised activity. Given the essential role of ASCL1 in neuronal development, such a mutation could have profound implications for normal neural function and development.The rs1170153450 identifier is a reference SNP cluster ID that provides a means to track the variant across different genomic databases and research studies. However, the papers provided do not contain specific information regarding the functional impact or clinical significance of this particular variant in the ASCL1 gene, nor do they mention the variant directly. Therefore, further studies would be required to elucidate the precise consequences of the c.2T>A p.Met1? variant on ASCL1 function and its potential association with disease phenotypes.

ゲノム変異 c.2T>A p.Met1? rs1170153450 は、ASCL1遺伝子に位置しています。この遺伝子は、アカイート-スキュート複合体ホモログ1（ASCL1）をコードしており、発達中の神経系における神経前駆細胞の決定と分化に重要な役割を果たす転写因子です。ASCL1は、神経新生に関連する遺伝子発現の調節にも関与しており、神経および神経内分泌細胞の分化における役割から、特定の種類の神経内分泌腫瘍の発生に関与している可能性が示唆されています。

c.2T>A変異は、標準的な開始コドン（ATGからAAGへの変化）の喪失を引き起こし、開始喪失変異をもたらすと予測されています。このタイプの変異は、タンパク質に重大な影響を与える可能性があり、翻訳の開始を妨げることで、タンパク質機能の完全な喪失や、活性が損なわれた短縮型タンパク質の生成につながる可能性があります。ASCL1が神経発達において重要な役割を果たしていることを考えると、このような変異は正常な神経機能と発達に深刻な影響を及ぼす可能性があります。

rs1170153450識別子は、異なるゲノムデータベースや研究においてこの変異を追跡するための参照SNPクラスターIDです。ただし、提供された論文には、このASCL1遺伝子内の特定の変異の機能的影響や臨床的意義に関する具体的な情報は含まれておらず、この変異について直接言及されているわけではありません。そのため、c.2T>A p.Met1?変異がASCL1の機能に与える正確な影響や疾患表現型との潜在的な関連性を解明するには、さらなる研究が必要です。
    
## References
- [1] Zhou YA et al. (2012). "Mutations of the phenylalanine hydroxylase gene in patients with phenylketonuria in Shanxi, China." Genetics and molecular biology, 35(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/23271928/)
- [2] Yang X et al. (2024). "The significance of machine learning in neonatal screening for inherited metabolic diseases." Frontiers in pediatrics, 12() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38577637/)
- [3] Nouruzi S et al. (2024). "ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer." JCI insight, 9(23) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39470735/)
- [4] Gao WH et al. (2011). "[Study on the mutations of phenylalanine hydroxylase gene in patients with phenylketonuria in Shanxi province]." Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 28(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/21811977/)
- [5] Yan YS et al. (2009). "[Mutation analysis of the PAH gene in patients with phenylketonuria in Gansu province]." Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 26(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/20017307/)
- [6] Marichal N et al. (2024). "Reprogramming astroglia into neurons with hallmarks of fast-spiking parvalbumin-positive interneurons by phospho-site-deficient Ascl1." Science advances, 10(43) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39454007/)
- [7] Wang L et al. (2017). "Mutation analysis of the phenylalanine hydroxylase gene and prenatal diagnosis of phenylketonuria in Shaanxi, China." Journal of pediatric endocrinology & metabolism : JPEM, 30(12) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29176022/)
- [8] Rubio A et al. (2016). "Rapid and efficient CRISPR/Cas9 gene inactivation in human neurons during human pluripotent stem cell differentiation and direct reprogramming." Scientific reports, 6() [PubMed](https://pubmed.ncbi.nlm.nih.gov/27857203/)
- [9] Parth Desai et al. (2023). "Abstract 5828: Distinct immunosuppressive tumor microenvironment modulates small cell lung carcinoma neuroendocrine phenotypic plasticity and heterogeneity" Cancer Research,  [PubMed](https://doi.org/10.1158/1538-7445.am2023-5828)
- [10] Su Z et al. (2014). "In vivo conversion of astrocytes to neurons in the injured adult spinal cord." Nature communications, 5() [PubMed](https://pubmed.ncbi.nlm.nih.gov/24569435/)
- [11] Gregory JA et al. (2020). "Cell Type-Specific In Vitro Gene Expression Profiling of Stem Cell-Derived Neural Models." Cells, 9(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32516938/)
- [12] Niceforo A et al. (2024). "Challenges and Efficacy of Astrocyte-to-Neuron Reprogramming in Spinal Cord Injury: In Vitro Insights and In Vivo Outcomes." bioRxiv : the preprint server for biology, () [PubMed](https://pubmed.ncbi.nlm.nih.gov/38585866/)
- [13] Toth JT et al. (2016). "BRET-monitoring of the dynamic changes of inositol lipid pools in living cells reveals a PKC-dependent PtdIns4P increase upon EGF and M3 receptor activation." Biochimica et biophysica acta, 1861(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26692031/)
- [14] Ouyang J et al. (2021). "RNA transcripts stimulate homologous recombination by forming DR-loops." Nature, 594(7862) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33981036/)
- [15] Wang LL et al. (2021). "Revisiting astrocyte to neuron conversion with lineage tracing in vivo." Cell, 184(21) [PubMed](https://pubmed.ncbi.nlm.nih.gov/34582787/)

    
## ClinVar Submissions

    